{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:23:51Z","timestamp":1785381831156,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL124055"],"award-info":[{"award-number":["HL124055"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000019","name":"National Hemophilia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1111\/jth.15768","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T12:18:12Z","timestamp":1653394692000},"page":"1928-1933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Factor VIIa treatment increases circulating extracellular vesicles in hemophilia patients: Implications for the therapeutic hemostatic effect of FVIIa"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0386-0543","authenticated-orcid":false,"given":"Kaushik","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7138-9362","authenticated-orcid":false,"given":"Usha R.","family":"Pendurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-1482","authenticated-orcid":false,"given":"Marylyn","family":"Manco\u2010Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-6000","authenticated-orcid":false,"given":"Erika J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-8523","authenticated-orcid":false,"given":"Donald F.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2099-0585","authenticated-orcid":false,"given":"L. Vijaya Mohan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15768_bb0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1160\/TH08-07-0434","article-title":"Factor VIIa and its potential therapeutic use in bleeding\u2010associated pathologies","volume":"100","author":"Hedner","year":"2008","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"10.1111\/jth.15768_bb0015","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.thromres.2010.01.025","article-title":"Platelet binding and activity of recombinant factor VIIa","volume":"125","author":"Hoffman","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15768_bb0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/2040620717737701","article-title":"Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date","volume":"8","author":"Giansily\u2010Blaizot","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1111\/jth.15768_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2003.11.006","article-title":"Experiences with recombinant human factor VIIa in patients with thrombocytopenia","volume":"41","author":"Goodnough","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.15768_bb0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0040-1718373","article-title":"The use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia","volume":"121","author":"Poon","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15768_bb0035","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/jth.14881","article-title":"Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet\u2010dependent and \u2010independent mechanisms","volume":"18","author":"Keshava","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15768_bb0040","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood.2020008417","article-title":"Factor VIIa induces extracellular vesicles from the endothelium; a potential mechanism for its hemostatic effect","volume":"137","author":"Das","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15768_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2021012358","article-title":"Factor VIIa suppresses inflammation and barrier disruption through the release of EEVs and transfer of microRNA 10a","volume":"139","author":"Das","year":"2022","journal-title":"Blood"},{"key":"10.1111\/jth.15768_bb0050","doi-asserted-by":"crossref","first-page":"e949","DOI":"10.1111\/j.1365-2516.2011.02492.x","article-title":"Monitoring rFVIIa 90 mug kg(\u2212)(1) dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h","volume":"17","author":"Brophy","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15768_bb0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1538-7836.2010.04152.x","article-title":"Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients","volume":"9","author":"Agerso","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15768_bb0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/hae.12110","article-title":"Monitoring rFVIII prophylaxis dosing using global haemostasis assays","volume":"19","author":"Al Hawaj","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15768_bb0065","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1111\/j.1365-2516.2010.02352.x","article-title":"First 20\u2009years with recombinant FVIIa (NovoSeven)","volume":"17","author":"Hedner","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15768_bb0070","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2516.2012.02864.x","article-title":"Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the haemophilia and thrombosis research society (HTRS) registry (2004\u20102008)","volume":"18","author":"Young","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15768_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-017-0160-y","article-title":"Preservation and storage stability of extracellular vesicles for therapeutic applications","volume":"20","author":"Jeyaram","year":"2017","journal-title":"AAPS J"},{"key":"10.1111\/jth.15768_bb0080","doi-asserted-by":"crossref","first-page":"e12162","DOI":"10.1002\/jev2.12162","article-title":"The impact of storage on extracellular vesicles: a systematic study","volume":"11","author":"Gelibter","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"10.1111\/jth.15768_bb0085","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/CIRCRESAHA.117.309417","article-title":"Methodological guidelines to study extracellular vesicles","volume":"120","author":"Coumans","year":"2017","journal-title":"Circ Res"},{"key":"10.1111\/jth.15768_bb0090","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/10717544.2021.1951896","article-title":"Preserving extracellular vesicles for biomedical applications: consideration of storage stability before and after isolation","volume":"28","author":"Yuan","year":"2021","journal-title":"Drug Deliv"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15768","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622020803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622020803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:34:58Z","timestamp":1761536098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622020803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1538783622020803"],"URL":"https:\/\/doi.org\/10.1111\/jth.15768","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor VIIa treatment increases circulating extracellular vesicles in hemophilia patients: Implications for the therapeutic hemostatic effect of FVIIa","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}